Zepp Health Corp (ZEPP) FinancialsZEPPZepp Health Corp

Zepp Health Corporation (ZEPP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Xiaomi Wearable Products, accounting for 72.5% of total sales, equivalent to CNY 546.02M. Another important revenue stream is Self-branded Products & Others. Understanding this composition is critical for investors evaluating how ZEPP navigates market cycles within the Phones & Handheld Devices industry.

Evaluating the bottom line, Zepp Health Corporation maintains a gross margin of 37.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -19.37%, while the net margin is -17.84%. These profitability ratios, combined with a Return on Equity (ROE) of -21.23%, provide a clear picture of how effectively ZEPP converts its operational activities into shareholder value.

In the context of the broader market, ZEPP competes directly with industry leaders such as FOSL and MOV. With a market capitalization of $54.55M, it holds a significant position in the sector. When comparing efficiency, ZEPP's gross margin of 37.35% stands against FOSL's 62.38% and MOV's 59.40%. Such benchmarking helps identify whether Zepp Health Corporation is trading at a premium or discount relative to its financial performance.

Zepp Health has shown mixed financial performance, with Q2 2026 revenue at $63.5 million, a 6.9% increase year-over-year, but a net loss of $11.33 million indicates ongoing financial challenges. The gross margin improved to 37.4%, suggesting some operational efficiency, but the overall financial health remains questionable.